Compare CCIF & HYFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCIF | HYFT |
|---|---|---|
| Founded | 2011 | 1983 |
| Country | United States | United States |
| Employees | N/A | 102 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.7M | 71.9M |
| IPO Year | N/A | N/A |
| Metric | CCIF | HYFT |
|---|---|---|
| Price | $3.19 | $1.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 124.6K | ★ 282.7K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | ★ 25.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $29.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.01 | $0.99 |
| 52 Week High | $6.61 | $3.00 |
| Indicator | CCIF | HYFT |
|---|---|---|
| Relative Strength Index (RSI) | 40.62 | 71.03 |
| Support Level | $3.01 | $1.56 |
| Resistance Level | $3.45 | $2.17 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 4.87 | 63.24 |
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.